Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 7/20 | 0.44 |
| ▸ | BCR | P11274 | 1/20 | 0.42 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
| ▸ | SMO | Q99835 | 3/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2940003 | 0.91 | HCRTR1 (0.44) | ABL1IGF1RSMOMCHR1HCRTR1 | |
| SCHEMBL2935161 | 0.90 | ABL1 (0.44) | ABL1IGF1RSMOMCHR1HCRTR1 | |
| SCHEMBL2934553 | 0.86 | IGF1R (0.45) | IGF1RSMO | |
| SCHEMBL2942481 | 0.85 | IGF1R (0.56) | IGF1RSMOPIK3CAHCRTR1HCRTR2 | |
| SCHEMBL3727642 | 0.85 | EPHX2 (0.40) | ABL1BCRIGF1RSMO | |
| SCHEMBL2986499 | 0.84 | ABL1 (0.40) | ABL1IGF1RSMOMCHR1SCN9A | |
| SCHEMBL2932135 | 0.83 | IGF1R (0.39) | ABL1IGF1RSMOMCHR1HCRTR1 | |
| SCHEMBL2933455 | 0.82 | SMO (0.45) | IGF1RSMOHCRTR1HCRTR2CYP3A4 | |
| SCHEMBL2935401 | 0.82 | SMO (0.45) | IGF1RSMOHCRTR1HCRTR2CYP3A4 | |
| SCHEMBL2938050 | 0.82 | HCRTR1 (0.50) | IGF1RSMOHCRTR1HCRTR2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825115-B2 | Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2010-11-02 | — | — | US | disclosed |
| EP-1599464-B1 | NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2010-09-22 | — | — | EP | disclosed |
| US-20080108654-A1 | Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-05-08 | — | — | US | disclosed |
| US-7354933-B2 | Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate | AVENTIS PHARMA SA (FR) | 2008-04-08 | — | — | US | disclosed |
| US-20040248884-A1 | Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108654-A1 | Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors | PRKG1, PRKACA, CMPK1 | ABL1 776/4885BCR 2102/4885IGF1R 1595/4885 |
| US-20040248884-A1 | Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | PRKG1, PRKACA, PRKCA | ABL1 683/4885BCR 1728/4885IGF1R 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.